Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) kicked off on Monday, up 3.41% from the previous trading day, before settling in for the closing price of $31.93. Over the past 52 weeks, CRNX has traded in a range of $24.10-$62.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -12.11% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -19.86%. With a float of $86.67 million, this company’s outstanding shares have now reached $93.53 million.
In an organization with 437 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.92%, operating margin of -49569.74%, and the pretax margin is -43191.05%.
Crinetics Pharmaceuticals Inc (CRNX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 7.49%, while institutional ownership is 104.80%. The most recent insider transaction that took place on Jun 12 ’25, was worth 3,141,877. In this transaction Chief Scientific Officer of this company sold 97,483 shares at a rate of $32.23, taking the stock ownership to the 99,713 shares. Before that another transaction happened on Jun 12 ’25, when Company’s Officer proposed sale 97,483 for $32.33, making the entire transaction worth $3,151,625.
Crinetics Pharmaceuticals Inc (CRNX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -19.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.30% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Take a look at Crinetics Pharmaceuticals Inc’s (CRNX) current performance indicators. Last quarter, stock had a quick ratio of 22.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8592.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.82, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.54 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.89 million. That was inferior than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 89.04%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 65.71%, which indicates a significant decrease from 92.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.27 in the past 14 days, which was lower than the 1.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.16, while its 200-day Moving Average is $41.32. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $33.61. Second resistance stands at $34.19. The third major resistance level sits at $35.00. If the price goes on to break the first support level at $32.22, it is likely to go to the next support level at $31.41. Assuming the price breaks the second support level, the third support level stands at $30.83.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
The company with the Market Capitalisation of 3.09 billion has total of 93,629K Shares Outstanding. Its annual sales at the moment are 1,040 K in contrast with the sum of -298,410 K annual income. Company’s last quarter sales were recorded 360 K and last quarter income was -96,770 K.
